AI Analysis
AI-generated analysis. Always verify with the original filing.
Dr. Reddy’s Laboratories Ltd. announced the launch of Obeda®, India’s first DCGI-approved generic semaglutide injection for type 2 diabetes, available in 2 mg and 4 mg pre-filled pens at INR 4,200 per month per patient. A Phase III study with 312 participants confirmed non-inferior efficacy and comparable safety to the innovator drug.
Key Takeaways
1First Indian company to receive DCGI approval for generic semaglutide
2Obeda® available in 2 mg and 4 mg strengths, pre-filled disposable pen for once-weekly subcutaneous administration
3Each pen delivers minimum 4 weekly doses; patient cost INR 4,200 per month for both strengths
4Phase III study enrolling 312 participants showed non-inferior efficacy, similar safety, and no anti-drug antibodies vs. innovator
5In-house API development, manufacturing, and formulation development
6Plans to introduce generic semaglutide in several countries subject to regulatory approval